Affiliation:
1. Department of Otorhinolaryngology-Head and Neck Surgery, Changhai Hospital, Second Military Medical University, Shanghai 200433, China
Abstract
Background:
There has been increased interest in the research of proteasome inhibitors
for more than two decades. Hotspots in this field are constantly changing.
Objective:
This study aimed to investigate trends in proteasome inhibitors research from 1992 to
2018 and compare the contributions of such research from different countries and authors.
Methods:
We used Excel 2013 and VoSviewer to analyze bibliometric data on the subject of
proteasome inhibitors, including the number of publications, citations frequency, H-index, and
country contributions and hotspots (keywords of popular scientific fields).
Results:
A total of 3646 articles were included. The USA contributed the largest percentage of
articles (1742), with the most citations (90666) and the highest H-index (139). The journal Blood had
the most articles. Dana Farber Cancer Institute and Millennium Pharmaceuticals Incorporation were
the most contributive institutions. Keywords could be divided into three clusters: Basic experiment,
clinical research, and others.
Conclusion:
The number of proteasome inhibitors articles has been increasing for the past 27 years.
The USA made the largest contribution in this field. Recent studies on the topic of “carfilzomib” are
relatively new and should be closely followed in proteasome inhibitors research.
Funder
National Nature Science Foundation of China
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,Pharmaceutical Science,Molecular Medicine
Reference35 articles.
1. Tsubuki S.; Saito Y.; Tomioka M.; Ito H.; Kawashima S.; Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-leucine and tri-leucine. J Biochem 1996,119(3),572
2. Galbiati F.; Volonte D.; Minetti C.; Bregman D.B.; Lisanti M.P.; Limb-girdle muscular dystrophy (LGMD-1C) mutants of caveolin-3 undergo ubiquitination and proteasomal degradation. Treatment with proteasomal inhibitors blocks the dominant negative effect of LGMD-1C mutanta and rescues wild-type caveolin-3. J Biochem 2000,275(48),37702-37711
3. Silke M.; Antje L.; Verena S.; Karl S.; Proteasome inhibitors: Poisons and remedies. Med Res Rev 2010,28(2),309-327
4. Rock K.L.; York I.A.; Saric T.; Goldberg A.L.; Protein degradation and the generation of MHC class I-presented peptides. Annu Rev Immunol 1999,17(17),739-779
5. Adams J.; Palombella V.J.; Sausville E.A.; Johnson J.; Destree A.; Lazarus D.D.; Maas J.; Pien C.S.; Prakash S.; Elliott P.J.; Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 1999,59(11),2615-2622